Using data from the GetGoal-Duo1, -L, and -L-Asia trials, the objectives of this study were to evaluate and compare the impact of lixisenatide once-daily add-on treatment to basal insulin therapy ± OADs among T2DM patients placed in different BMI categories at the baseline; BMI <25 kg/m2, 25–<30 kg/m2, 30–<35 kg/m2 and ≥35 kg/m2. Here, INS is linked to type 2 diabetes mellitus.